With the changes in modern society's diet, an increasing number of people are facing risks such as obesity, hyperlipidemia, fatty liver, type II diabetes, and cardiovascular and cerebrovascular diseases. To meet market demands, Weitongda has constructed relevant mouse models for the study of hyperlipidemia, lipid metabolism, and dysregulation of glycolipid metabolism, as well as humanized mice for popular therapeutic target genes like PCSK9 and HSD17B13, based on the GEMS platform and through gene editing technology. These models are suitable for the study of small nucleic acid drugs and antibody drugs targeting these types of therapeutic targets.